The dollar volume of the leading provider of therapeutics for men’s health Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) on Thursday was approximately 1.13 million, with over 0.29 million shares trading and a closing price of $3.89. A positive weekly performance of 21.56% was recorded by Petros stock over the past 5 sessions, and the stock’s price on March 25th improved nearly 19.33%.
The public owns 9.69 million shares of PTPI stock and among those, 6.11 million shares have been available for trading. This surge in PTPI stock occurred despite the lack of any relevant news, but the previous development shared this month may give a better idea of where Petros will go.
Where Petros is heading to?
Petros is dedicated to providing the best possible men’s healthcare through the identification, development, acquisition, and commercialization of innovative therapeutics related to men’s health issues. Among those are erectile dysfunction, endothelial dysfunction, psychosocial problems, Peyronie’s disease, hormonal health, substance abuse, and other illnesses.
Stendra (avanafil) was used to investigate endothelial function in men suffering from erectile dysfunction (ED). The findings were released last week by Petros Pharmaceuticals in a publication.
- This FDA-approved treatment for erectile dysfunction is currently one of the bestselling products in the US.
- Stendra’s label will be expanded to potentially include improved endothelial function through the use of this research, Petros plans.
- Endothelial dysfunction is the impairment of nitric oxide levels within blood vessels. It is often associated with impaired blood vessel function.
- The disease of endothelial dysfunction occurs in the same proportion as diabetes, hypertension, and dyslipidemia.
A previous label expansion was carried over by Petros (PTPI) from Stendra’s FDA approval date in 2013 to its FDA approval date in 2014, resulting in Stendra being the only prescription ED medication in the marketplace which will be putting PTPI ahead of the peers.